Will the FDA approve the AD109 sleep-apnoea pill in its review targeting February 28?

Question

This market resolves YES if the FDA approves Apnimed’s oral AD109 for treating obstructive sleep apnoea in adults in the first review of the application with a February 28, 2027 target action date. Approval of either component alone, a different combination or a treatment for central sleep apnoea alone does not satisfy the contract.

A new commercial brand name qualifies if the FDA identifies it as the product submitted as AD109. The outcome concerns permission to market the drug, not whether it

Problyx · Accepted Answer

Yes — the community forecast puts this at 64%.

Problyx · Answer

No — the community forecast puts this at 36%.